AZ sponsor cfDNA testing EQA scheme

1 year ago

Astrazeneca sponsor EQA scheme for cfDNA testing for EGFR mutations in Lung cancer

On the 26th February 2020 EMQN CIC and GenQA announced that they were collaborating to launch an EQA Scheme for cfDNAtesting for EGFR mutations in Lung cancer, with the purpose of promoting high quality testing.

We are delighted to announce that AstraZeneca have agreed to fund laboratory participation in the scheme through the provision of an unrestricted educational grant. Participation in the scheme will therefore be FREE.

  • If you have already registered for the scheme then we will credit your account to ensure that participation costs are withdrawn.
  • If you have NOT registered, please log in to your account and enrol for the scheme. The closing date has been extended to 30th April 2020.

Capacity is capped at 300 laboratories and we only have 70 spaces left so please register quickly if you want to guarantee a place on the scheme.

Next: EMQN collaborates with QCMD to launch Coronavirus Outbreak Preparedness EQA Pilot
Translate »